Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has received a consensus rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $23.00.
Several analysts have recently issued reports on CMTA shares. Zacks Investment Research cut shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Bloom Burton reaffirmed a “buy” rating on shares of Clementia Pharmaceuticals in a research report on Sunday, December 16th. Finally, Robert W. Baird started coverage on shares of Clementia Pharmaceuticals in a research report on Friday, January 18th. They set an “outperform” rating and a $24.00 price objective for the company.
Shares of CMTA stock traded up $0.09 during midday trading on Friday, reaching $14.09. 300 shares of the company traded hands, compared to its average volume of 34,927. Clementia Pharmaceuticals has a 1-year low of $8.10 and a 1-year high of $19.58. The company has a market cap of $444.08 million, a price-to-earnings ratio of -1.76 and a beta of -0.05.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
Further Reading: What is the quiet period?
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.